Pharmaceuticals

20 stories about Pharmaceuticals
מנכ"ל טבע החדש קור שולץ 2

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer
The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
מנכ"ל טבע החדש קור שולץ 2

As U.S. Domestic Issuer, Teva Reveals Top Stock Owners

03.01.18|Dror Reich
Kåre Schultz, the newly-appointed CEO of generic drugmaker Teva Pharmaceutical Industries Ltd., is one of Teva's largest shareholders, a Wednesday filing to the U.S. Securities and Exchange Commission revealed
שם: מעבדה ביוטק וושי אפטק Lab Biotech WuXi AppTec

Merck, China’s WuXi AppTec to Launch Biotech Incubator in Israel

25.12.17|Meir Orbach
Israel-born businessman Mori Arkin and life sciences-focused venture capital fund Pontifax are also partners in the venture, set to launch in 2018
default image

Following Restructuring Announcements, Teva Reinstated as Israel’s Biggest Company

18.12.17|Lilach Baumer
Teva's stock jumped 18.7% on the New York Stock Exchange between Thursday market opening and Friday market close. Israeli Prime Minister Benjamin Netanyahu is expected to meet with CEO Kåre Schultz Tuesday
אחרי ה שביתה נתב"ג טבע פיטורים טיסות טרמינל

Tel Aviv Airport, Stock Market Open as Solidarity Strike Ends

17.12.17|Lior Gutman, Omri Milman and Micky Grunfeld
Israel’s largest labor union called for a half-day strike on Thursday, in support of Teva employees
פסקל סוריו מנכ"ל AstraZeneca

Once Future CEO Could have Taken Teva on a Different Path

14.12.17|Lilach Baumer, Golan Hazani, and Orr Hirschauge
AstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
מנכ"ל טבע החדש קור שולץ 2

Teva to Cut Around Half of Israeli Workforce, Outsource Operations

13.12.17|Dror Reich
An internal document reviewed by Calcalist reveals the troubled drugmaker's detailed domestic cost-cutting plans
מפעל טבע טק ב רמת חובב

Teva to Cut Jobs, Shut Down Some Israeli Operations

13.12.17|Dror Reich and Sefi Krupsky
On Thursday, the troubled drugmaker is expected to unveil its cutback plan. At its center is extensive layoffs and the reorganization and divestment of non-core assets
יצחק פטרבורג

Former Chairman Yitzhak Peterburg Leaves Teva

13.12.17|Lilach Baumer
Mr. Peterburg was the troubled drugmaker's interim CEO between February and November 1, when Kåre Schultz took helm
מנכ"ל טבע החדש קור שולץ 1

Teva to Unveil Strategic Plan, Layoffs Thursday

12.12.17|Dror Reich
Last month the debt-riddled drug maker announced a rehabilitation plan amidst rumors of upcoming employee cuts
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
חברת ה תרופות טבע Teva

Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker

30.11.17|Anat Rouah
Tel Aviv-based capital investment firm Tulip Capital is threatening derivative action against Teva, saying the company's huge debt load renders its dividends unlawful
מנכ"ל טבע החדש קור שולץ

New CEO Steers Teva Back to Generics

28.11.17|Golan Hazani and Dror Reich
A reorganization plan announced by the company Monday would see the troubled drugmaker return to its core competencies, despite market pressures
default image

Biomed Company Protalix to Lay Off a Fifth of its Workforce

26.11.17|Dror Reich
The Israel-based NYSE American-listed company is currently undergoing a streamlining process
חממה של BOL קנאביס

Cannabis Breeder Barney's Farm Invests in Israeli Cannabis Company

23.11.17|Dror Reich
Barney's made a strategic investment of $2.1 million in Tel Aviv-listed Medivie Therapeutic Ltd., a company setting up a medical cannabis farm and pharmacy venture
default image

Perrigo Completes Sale of Israel Business for $110 million

23.11.17|Lilach Baumer
The buyer, New York-based investment firm SK Capital, has $1.9 billion assets under management
מנכ"ל טבע החדש קור שולץ 2

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
ראג'יב מאליק נשיא מיילן

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich
Mylan is currently the highest valued company on the TASE at $18.5 billion
תרופות  טבע גלולות תרופה

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer
The clinical stage company develops treatments mostly for osteoporosis and bone disorders
מטה טבע פתח תקווה

Fitch Downgrades Teva to Junk Rating

07.11.17|Yaniv Rahimi
The U.S. credit agency changed Teva's rating from BBB to BB, with a negative outlook, due to "significant operational stress." The downgrade might affect Teva's ability to take on additional debt